Neuroleptics in acute mania: a pharmacoepidemiologic study

Ann Pharmacother. 1996 Dec;30(12):1396-8. doi: 10.1177/106002809603001206.

Abstract

Objective: To provide an epidemiologic descriptive analysis of the acute drug treatment of inpatients with bipolar mania in state psychiatric facilities in 1990.

Methods: We surveyed the first 3 weeks of drug treatment of all inpatients with bipolar mania who were admitted to 22 New York State adult psychiatric facilities during a 6-month period (n = 528).

Results: Almost all patients with mania were treated with neuroleptics. The mean +/- SD neuroleptic dosage was 684 +/- 543 mg/d chlorpromazine equivalents. Sixty-one percent of the patients received lithium and 12% received carbamazepine or valproate. Neuroleptic dosage was related to age, with older patients receiving lower dosages. Patients receiving combination treatment of a neuroleptic with either lithium, an anticonvulsant, or a benzodiazepine received a mean neuroleptic dosage similar to that of patients treated with a neuroleptic alone.

Conclusions: Although their use has been widely discouraged for mood disorders, neuroleptics have been the standard treatment for acute mania.

MeSH terms

  • Adult
  • Analysis of Variance
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Bipolar Disorder / drug therapy*
  • Drug Therapy, Combination
  • Female
  • Hospitals, Psychiatric
  • Humans
  • Inpatients
  • Male
  • Pharmacoepidemiology

Substances

  • Antipsychotic Agents